OTCMKTS:IGXT IntelGenx Technologies (IGXT) Stock Price, News & Analysis $0.17 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.1752-Week Range$0.09▼$0.22VolumeN/AAverage VolumeN/AMarket Capitalization$29.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get IntelGenx Technologies alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About IntelGenx Technologies Stock (OTCMKTS:IGXT)IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Read More IGXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGXT Stock News HeadlinesJuly 20, 2024 | finanznachrichten.deIntelGenx Technologies Corp.: IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 19, 2024 | globenewswire.comIntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 3, 2024 | globenewswire.comIntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseJune 11, 2024 | globenewswire.comIntelGenx Announces Initiation of the Sale and Investment Solicitation ProcessMay 28, 2024 | globenewswire.comIntelGenx Obtains Court-Approval of a Sale and Investment Solicitation ProcessMay 17, 2024 | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesMay 17, 2024 | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 8, 2024 | globenewswire.comIntelGenx Announces Voting Results on Election of DirectorsApril 8, 2024 | finance.yahoo.comIntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical TrialApril 8, 2024 | globenewswire.comIntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical TrialApril 5, 2024 | globenewswire.comIntelGenx Updates Status of Buprenorphine Buccal Film ANDAMarch 23, 2024 | seekingalpha.comIntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | insidermonkey.comIntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | investorplace.comIGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023March 21, 2024 | globenewswire.comIntelGenx Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 16, 2024 | seekingalpha.comIGXT IntelGenx Technologies Corp.See More Headlines Receive IGXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IGXT CUSIP45822R101 CIK1098880 Webwww.intelgenx.com Phone(514) 331-7440Fax514-331-0436Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,930,000.00 Net Margins-1,049.48% Pretax Margin-1,049.48% Return on EquityN/A Return on Assets-158.32% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.12 Sales & Book Value Annual Sales$1.04 million Price / Sales28.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-2.39Miscellaneous Outstanding Shares174,660,000Free Float101,214,000Market Cap$29.17 million OptionableNot Optionable Beta2.60 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Dwight Gorham (Age 66)Chief Executive Officer Comp: $230.56kMr. André Godin C.A. (Age 60)CPA, CA, CPA, President & CFO Comp: $261.62kMr. Tommy Kenny J.D. (Age 37)L.L.B., M.Sc., Senior VP & General Counsel Comp: $152.62kMs. Nadine Paiement M.Sc. (Age 47)Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp Comp: $156.5kMs. Karen Kalayajian CPA (Age 44)Vice President of Finance & Administration Stephen KilmerInvestor Relations OfficerMs. Ingrid Zerbe (Age 70)Corporate Secretary Zenoz Nina PourhassanVP of Quality Operations of SubsidiaryMore ExecutivesKey CompetitorsTelomir PharmaceuticalsNASDAQ:TELOKaryopharm TherapeuticsNASDAQ:KPTIAdageneNASDAQ:ADAGRegulus TherapeuticsNASDAQ:RGLSPyroGenesis CanadaNASDAQ:PYRGFView All Competitors IGXT Stock Analysis - Frequently Asked Questions How have IGXT shares performed this year? IntelGenx Technologies' stock was trading at $0.1381 at the beginning of the year. Since then, IGXT shares have increased by 20.9% and is now trading at $0.1670. View the best growth stocks for 2024 here. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (OTCMKTS:IGXT) announced its earnings results on Wednesday, May, 15th. The company reported ($0.02) EPS for the quarter. The company had revenue of $0.17 million for the quarter. How do I buy shares of IntelGenx Technologies? Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include Cronos Group (CRON), Zevra Therapeutics (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL) and This page (OTCMKTS:IGXT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IntelGenx Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.